Health Care & Life Sciences » Biotechnology | Benitec Biopharma Ltd.

Benitec Biopharma Ltd. | Balance Sheet

Fiscal year is July-June. All values AUD Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
31,359.20
21,787.00
18,230.00
17,475.00
16,115.00
Total Accounts Receivable
121.60
123.00
977.00
4,406.00
4,255.00
Other Current Assets
2,966.70
3,154.00
177.00
281.00
525.00
Total Current Assets
34,447.50
25,064.00
19,384.00
22,162.00
20,895.00
Net Property, Plant & Equipment
47.70
456.00
506.00
445.00
319.00
Other Assets
-
-
-
59.00
125.00
Total Assets
34,495.20
25,520.00
19,890.00
22,666.00
21,339.00
Accounts Payable
572.60
760.00
538.00
174.00
580.00
Other Current Liabilities
382.10
882.00
497.00
951.00
1,967.00
Total Current Liabilities
954.70
1,642.00
1,035.00
1,125.00
2,547.00
Provision for Risks & Charges
-
-
18.00
35.00
48.00
Total Liabilities
954.70
1,642.00
1,053.00
1,160.00
2,595.00
Common Equity (Total)
33,540.50
23,878.00
18,837.00
21,506.00
18,744.00
Total Shareholders' Equity
33,540.50
23,878.00
18,837.00
21,506.00
18,744.00
Total Equity
33,540.50
23,878.00
18,837.00
21,506.00
18,744.00
Liabilities & Shareholders' Equity
34,495.20
25,520.00
19,890.00
22,666.00
21,339.00

About Benitec Biopharma

View Profile
Address
99 Mount Street
North Sydney New South Wales (NSW) 2060
Australia
Employees -
Website http://www.benitec.com
Updated 07/08/2019
Benitec Biopharma Ltd. engages in the development of therapeutics based on patented gene silencing technology called ddRNAi. It develops treatments for chronic and life threatening human conditions, such as oculopharyngeal muscular dystrophy, oncology, wet age-related macular degeneration, and hepatitis B. It operates through the Australia and USA geographical segments.